Key Highlights
- Moderna shares jumped over 16% following the publication of Phase 3 results for mRNA-1010 in the New England Journal of Medicine, demonstrating superior efficacy compared to a standard-dose seasonal flu vaccine in participants aged 50 and above.
- Following Q1 2026 earnings, three Wall Street firms increased their price targets: Evercore ISI raised theirs to $50, Goldman Sachs adjusted to $49, and Piper Sandler launched coverage with a Buy recommendation.
- A hantavirus outbreak traced to a cruise traveling from Argentina to Cabo Verde temporarily drew attention to Moderna’s early-phase hantavirus research program, although analysts indicate minimal commercial prospects in this area.
- Regulatory authorities have scheduled an August 5 PDUFA decision date for mRNA-1010, with additional submissions pending review in Europe, Canada, and Australia.
- Pfizer and BioNTech discontinued recruitment for a significant U.S. COVID vaccine study targeting the 50–64 age group after encountering insufficient enrollment.
Moderna shares reached approximately $56 during Thursday trading, marking a gain exceeding 16% for the session. This upward movement stemmed from robust clinical trial outcomes, multiple Wall Street endorsements, and brief attention surrounding hantavirus developments.
The primary catalyst came from clear clinical evidence: Phase 3 results for Moderna’s mRNA-based influenza vaccine candidate, mRNA-1010, appeared in the New England Journal of Medicine. The published data demonstrated that the vaccine achieved its predefined superiority endpoint when compared against a licensed standard-dose seasonal influenza vaccine in individuals aged 50 years and older.
This achievement represents a significant milestone. Demonstrating superior performance against an already-approved vaccine in a peer-reviewed publication strengthens Moderna’s regulatory submission as the company approaches a critical FDA decision point.
Regulatory authorities have designated August 5 as the PDUFA target date for mRNA-1010. Additional regulatory submissions remain under evaluation in Europe, Canada, and Australia, positioning this as a potentially global product launch pending approval decisions.
Wall Street analysts amplified the momentum. Evercore ISI increased its price target from $35 to $50. Goldman Sachs adjusted its forecast from $43 to $49. Piper Sandler launched coverage with a Buy recommendation. These adjustments followed Moderna’s Q1 2026 earnings release.
Hantavirus Developments Created Brief Market Attention
A hantavirus outbreak among passengers aboard a Dutch-flagged cruise vessel traveling from Argentina to Cabo Verde briefly elevated Moderna shares during early trading hours. Eight cases emerged, including three fatalities, with five confirmed as the Andes virus strain — the sole hantavirus variant documented to demonstrate limited person-to-person transmission capability.
The WHO assessed the public health risk as minimal. Dr. Maria Van Kerkhove addressed reporters directly at Thursday’s press conference: “This is not the start of a COVID pandemic.”
Evercore ISI highlighted a Moderna partnership with Korea University focused on hantavirus research initiated in 2023, while simultaneously tempering expectations. The firm stated it identifies “no meaningful revenue opportunity” from the outbreak-related headlines and emphasized that Moderna’s hantavirus candidate “remains very early stage.” The analysts observed that the stock “tends to trade on outbreak headlines well beyond the underlying commercial implications.”
To summarize: hantavirus news generated temporary interest, while the influenza vaccine data and analyst endorsements provided the substantial price movement.
Cruise Industry Stocks Experienced Declines
Cruise line equities faced downward pressure following the hantavirus reports. Royal Caribbean declined approximately 2% during the session, while Carnival experienced a comparable decrease. Norwegian Cruise Line Holdings dropped nearly 3%. Viking Holdings and Lindblad Expeditions each fell around 2.5%.
Regarding competitive dynamics, Pfizer and BioNTech terminated enrollment for a major U.S. COVID vaccine clinical trial focused on adults aged 50 to 64, attributing the decision to insufficient participant recruitment. This development may enhance Moderna’s relative standing in the evolving vaccine landscape.
Broader market indices provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow increasing 0.21%, and the Nasdaq climbing 1.16%.
Moderna’s stock concluded the previous trading session at $48.79. The August 5 FDA decision date for mRNA-1010 represents the next significant milestone for investors to monitor.
